Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis by unknown
POSTER PRESENTATION Open Access
Phase I/II clinical trial of anti-OX40, radiation and
cyclophosphamide in patients with prostate
cancer: immunological analysis
Magdalena Kovacsovics-Bankowski*, Lana Chisholm, Jonna Vercellini, Marka Crittenden, Scot Lary, Brendan Curti,
Andrew Weinberg
From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013
Introduction
OX40, a member of the Tumor Necrosis Factor Receptor
superfamily is a potent co-stimulatory molecule. OX40
engagement increases T cell proliferation, effector function
and survival. Pre-clinical studies have shown that OX40
agonist synergizes with radiation and cyclophosphamide
to increase survival. A phase I clinical trial has shown that
anti-OX40 mAb was well tolerated and induced prolifera-
tion of CD8 and CD4 non-Treg cells in the peripheral
blood (PB).
Methods
This trial was design to evaluate the toxicity and the effect
on peripheral blood lymphocytes of cyclophosphamide
and radiation in combination with anti-OX40 agonist
in patients with metastatic castrate- and chemotherapy-
resistant prostate cancer. The immunological analysis was
performed on peripheral blood lymphocytes (PBL) using a
multi-color flow analysis panel containing CD3, CD4,
CD8, CD95, CD25, CD38, HLA-DR and the intracellular
markers, FoxP3 and Ki-67.
Results
Anti-OX40, Cyclophosphamide and radiation had man-
ageable safety and tolerability profile. Transient decreases
in PSA were observed in 4/9 patients. Four patients had
an increase in PSA DT. In 5/9 patients, bone and lymph
node metastases were radiographically stable during the
study observation. The immunological response measured
in the PB shows a 2-3.5-fold increase in the proliferating
CD4+ CD95+ T cells, mostly in the FoxP3- population.
In the 3rd cohort, there was also a 3 fold increase, in CD4
+ FoxP3+ T cells proliferation (Treg). The proportion of
cycling CD8+ CD95+ T cells peaked with a 5-6-fold
increase of cycling cells. NK cell proliferation was also
observed, with a 2-4.5 fold proliferation increase. In the
first anti-OX40 clinical trial, we have observed that the
administration of anti-OX40 antibody increased the acti-
vation status of the CD8+ T cells as measured by the
co-expression of CD38 and HLA-DR on the cycling cells.
A similar trend was observed in this study. In some
patients, the administration of anti-OX40 modified the
cytokine profile of PBMC. We have observed an increase
in IFNg and IL-2, with stable TNFa secretion and a
decrease in IL-6, IL-10 and IL-17.
Summary
Administration of anti-OX40 with radiation and cyclopho-
sphamide has not affected the degree of proliferation of
PBL. We have observed a similar fold increase in the pro-
liferation of CD4+ FoxP3-, CD8+ and NK cells as in the
first clinical trial. With the exception of cohort #3 (highest
dose of cyclophosphamide), there was no change in the
proliferation of CD4+ FoxP3+ T cells (Treg). There was a
trend towards a higher percentage of cycling CD8+ T cells
expressing the activation markers CD38 and HLA-DR.
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